Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Breast Cancer
61%
Breast Cancer Patients
44%
Human Epidermal Growth Factor Receptor 2 (HER2)
38%
Early Breast Cancer
30%
Overall Survival
22%
Metastatic Breast Cancer
19%
Tumor
19%
Chemotherapy
18%
Primary Breast Cancer
15%
Adjuvant Chemotherapy
15%
Adjuvant Therapy
14%
Trastuzumab
14%
Cyclophosphamide
13%
Epirubicin
12%
Cancer Cooperative Group
12%
ER+ Breast Cancer
11%
Treatment Lines
10%
Estrogen Receptor-positive
10%
Fluorouracil
10%
Advanced Breast Cancer
9%
Postmenopausal Women
9%
Docetaxel
9%
Denmark
8%
Endocrine Therapy
8%
Breast Cancer Risk
8%
Meta-analysis
8%
Breast Cancer Treatment
8%
PIK3CA mutation
7%
95% Confidence Interval
7%
Aromatase Inhibitors
7%
Aberrations
7%
Methotrexate
6%
Plasminogen Activator inhibitor-1 (PAI-1)
6%
Medical Treatment
6%
High Risk
6%
Fluorescence in Situ Hybridization
6%
Electronic Patient-reported Outcome (ePRO)
6%
Hazard Ratio
6%
Anthracyclines
6%
Progression-free Survival
6%
Recurrence Rate
6%
Estrogen Receptor
6%
Recurrence Risk
6%
Node Positive
5%
Immunohistochemistry
5%
HER2-positive Metastatic Breast Cancer
5%
Breast Carcinoma
5%
Prognostic Value
5%
Median Progression-free Survival
5%
Human Epidermal Growth Factor Receptor 2-positive Breast Cancer (HER2-positive breast cancer)
5%
Medicine and Dentistry
Breast Cancer
100%
Metastatic Breast Cancer
29%
Overall Survival
26%
Chemotherapy
17%
Epidermal Growth Factor Receptor 2
14%
Gamma Urogastrone
14%
Tumor
14%
Progression Free Survival
13%
Estrogen Receptor
13%
Adjuvant Chemotherapy
12%
Recurrent Disease
12%
Hormone Therapy
11%
Diseases
10%
Neoplasm
9%
Trastuzumab
9%
Adjuvant Therapy
9%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
8%
Aromatase Inhibitor
7%
Malignant Neoplasm
7%
Fulvestrant
7%
Palbociclib
7%
Patient-Reported Outcome
6%
Recurrence Risk
5%
Letrozole
5%
Cancer
5%
Observational Study
5%
Retrospective Study
5%
Disease Free Survival
5%
Postmenopause
5%
Genetics
5%
Hormone Receptor
5%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
79%
Overall Survival
19%
Trastuzumab
16%
Epirubicin
15%
Epidermal Growth Factor Receptor 2
15%
Cyclophosphamide
15%
Metastatic Breast Cancer
14%
Chemotherapy Regimens
13%
Gamma Urogastrone
13%
Docetaxel
11%
Recurrent Disease
11%
Disease Free Survival
10%
Anthracycline
9%
Fluorouracil
9%
Malignant Neoplasm
8%
Progression Free Survival
8%
Fulvestrant
7%
Plasminogen Activator Inhibitor 1
6%
Methotrexate
6%
Retrospective Study
6%
Neoplasm
6%
Estrogen Receptor
6%
Aromatase Inhibitor
5%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
5%